You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer

 

Online download statistics by month:

Online download statistics by month: November 2023 to July 2025

AbstractFullPdf
Nov 2023444028
Dec 2023133022
Jan 2024142014
Feb 2024144015
Mar 2024332044
Apr 2024530040
May 2024216023
Jun 2024318034
Jul 2024456049
Aug 2024138920870
Sep 202463380315
Oct 202428580162
Nov 202420680128
Dec 20242437090
Jan 20252020096
Feb 2025807089
Mar 20250050
Apr 20250038
May 20250057
Jun 20251041
Jul 2025001
Total3313602206